
Investors’ data
Latest news
- December 10, 2008
Thallion Announces a Review of Strategic Alternatives
- November 18, 2008
Thallion Initiates Enrollment in Phase II Metastatic Melanoma Trial
- October 24, 2008
Thallion's TLN-4601 Inhibits Mutated K-RAS Signaling in Cancer Cells
Documentation
Corporate Governance
Thallion Pharmaceutical Inc. and its Board of Directors believe that transparent and sound corporate governance practices are critical to the Company’s long-term success.
The Board believes that the Company’s corporate governance practices are well aligned with the recommendations contained in the various applicable guidelines and regulations issued by the Toronto Stock Exchange (TSX Guidelines) and other securities regulators.
For further information, please refer to our corporate profile on SEDAR.
